Taken together, these studies provide evidence to support the notion that altered Shh signalling may be an important developmental factor in the pathobiology of mental illnesses and could be an alternative target for therapeutic drug development for these disorders, although establishment of appropriate time windows for intervention and the potential for oncogenic effects would merit caution. This evidence concerns the gene SHH and psychiatric disorder.